Nav: Home

Science Current Events and Science News | Brightsurf | March 31, 2019


HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma
A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
Excess body weight before 50 is associated with higher risk of dying from pancreatic cancer
Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at older ages, according to results of a study presented at the AACR Annual Meeting 2019, March 29-April 3.
Liquid crystals could help deflect laser pointer attacks on aircraft
Aiming a laser beam at an aircraft isn't a harmless prank: The sudden flash of bright light can incapacitate the pilot, risking the lives of passengers and crew.
Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma
A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among patients with rare, high-grade neuroendocrine carcinoma, according to results from the DART phase II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
Fish slime: An untapped source of potential new antibiotics
As current antibiotics dwindle in effectiveness against multidrug-resistant pathogens, researchers are seeking potential replacements in some unlikely places.
New glioblastoma vaccine shows promising results in phase Ib clinical trial
A brain-cancer vaccine more than 20 years in the making suspends cancer growth in patients enrolled in early-stage trial.
CD40 combination therapy can shrink pancreatic tumors
A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients.
Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors
A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
Understanding what makes Tennessee whiskey unique
Freshly distilled, un-aged whiskey is filtered over charcoal made from the sugar maple tree in a mysterious, but necessary step known as the Lincoln County Process.
Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients
Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who had EGFR-mutant non-small cell lung cancer (NSCLC) that had developed resistance to prior EGFR-targeted therapies through MET-gene amplification, according to interim results from two expansion cohorts of the phase Ib clinical trial TATTON, presented at the AACR Annual Meeting 2019, March 29-April 3.
Immunotherapy combination effective for patients with rare neuroendocrine cancer
A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta.
Next-generation single-dose antidotes for opioid overdoses
Fentanyl's powerful effects are long-lasting, and even tiny amounts of the drug can lead to an overdose.

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...